Abstract
Background
Reduced Environmental Stimulation Therapy via floatation (floatation-REST) is a behavioral intervention designed to attenuate exteroceptive sensory input to the nervous system. Prior studies in anxious and depressed individuals demonstrated that single sessions of floatation-REST are safe, well-tolerated, and associated with an acute anxiolytic and antidepressant effect that persists for over 48 hours. However, the feasibility of using floatation-REST as a repeated intervention in anxious and depressed populations has not been well-investigated.
Methods
In this single-blind safety and feasibility trial, 75 individuals with anxiety and depression were randomized to complete six sessions of floatation-REST in different formats: pool-REST (weekly 1-hour float sessions), pool-REST preferred (float sessions with flexibility of duration and frequency), or an active comparator (chair-REST; weekly 1-hour sessions in a Zero Gravity chair). Feasibility (primary outcome) was assessed via an 80% rate of adherence to the assigned intervention; tolerability via study dropout and duration/frequency of REST utilization; and safety via incidence of adverse events and ratings about the effects of REST.
Results
Of 1,715 individuals initially screened, 75 participants were ultimately randomized. Six-session adherence was 85% for pool-REST (mean, M = 5.1 sessions; standard deviation, SD = 1.8), 89% for pool-REST preferred (M = 5.3 sessions; SD = 1.6), and 74% for chair-REST (M = 4.4 sessions; SD = 2.5). Dropout rates at the end of the intervention did not differ significantly between the treatment conditions. Mean session durations were 53.0 minutes (SD = 12.3) for pool-REST, 75.4 minutes (SD = 29.4) for pool-REST preferred, and 58.4 minutes (SD = 4.3) for chair-REST. There were no serious adverse events associated with any intervention. Positive experiences were endorsed more commonly than negative ones and were also rated at higher levels of intensity.
Conclusions
Six sessions of floatation-REST appear feasible, well-tolerated, and safe in anxious and depressed individuals. Floatation-REST induces positively-valenced experiences with few negative effects. Larger randomized controlled trials evaluating markers of clinical efficacy are warranted.
Clinical Trial Registration Identifier
NCT03899090.
Funder
William K. Warren Foundation
National Center for Complementary and Integrative Health
National Institute of Mental Health
National Institute of General Medical Sciences
Publisher
Public Library of Science (PLoS)
Reference52 articles.
1. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication;RC Kessler;Archives of General Psychiatry,2005
2. Global Health Estimates 2019: Disease burden by Cause, Age, Sex, by Country and by Region, 2000–2019. Geneva: World Health Organization; 2020.
3. Comorbid depression and anxiety spectrum disorders;JM Gorman;Depression and Anxiety,1996
4. Comorbidity of mood and anxiety disorders;J Kaufman;Depression and Anxiety,2000
5. Comorbidity of anxiety and unipolar mood disorders;S Mineka;The Science of Mental Health: Compulsive disorder and Tourette’s syndrome,2001